|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-0.71/-0.23
|
企業價值
47.50M
|
資產負債 |
每股賬面淨值
1.01
|
現金流量 |
現金流量率
--
|
損益表 |
收益
2.09M
|
每股收益
0.21
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2025/01/11 11:21 EST
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products. |